Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2024-2030

Page: 141

Published Date: 23 Feb 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report studies the global Chimeric Antigen Receptor (CAR)-T Cell Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Chimeric Antigen Receptor (CAR)-T Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Chimeric Antigen Receptor (CAR)-T Cell Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy total market, 2019-2030, (USD Million)
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy total market, key domestic companies and share, (USD Million)
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy revenue by player and market share 2019-2024, (USD Million)
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy total market by Type, CAGR, 2019-2030, (USD Million)
Global Chimeric Antigen Receptor (CAR)-T Cell Therapy total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Autolus Therapeutics, CARsgen Therapeutics, Juno Therapeutics, Sorrento Therapeutics, bluebird bio, CELGENE CORPORATION, Eureka Therapeutics, Avacta Life Sciences and Calyxt, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Chimeric Antigen Receptor (CAR)-T Cell Therapy market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, Segmentation by Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market, Segmentation by Application
Hospital
Diagnostic Center
Other

Companies Profiled:
Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics

Key Questions Answered
1. How big is the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market?
2. What is the demand of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market?
3. What is the year over year growth of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market?
4. What is the total value of the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market?
5. Who are the major players in the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market?

Table of Contents

1 Supply Summary
    1.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Introduction
    1.2 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Total Market by Region (by Headquarter Location)
        1.3.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.3 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.4 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.5 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.6 South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.7 ASEAN Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
        1.3.8 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Major Market Trends

2 Demand Summary
    2.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.2 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region
        2.2.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2019-2024)
        2.2.2 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Region (2025-2030)
    2.3 United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.4 China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.5 Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.6 Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.7 South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.8 ASEAN Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)
    2.9 India Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030)

3 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies Competitive Analysis
    3.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Chimeric Antigen Receptor (CAR)-T Cell Therapy in 2023
        3.2.3 Global Concentration Ratios (CR8) for Chimeric Antigen Receptor (CAR)-T Cell Therapy in 2023
    3.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Company Evaluation Quadrant
    3.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Overall Company Footprint Analysis
        3.4.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Region Footprint
        3.4.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
        3.4.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Comparison
        4.2.1 United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies and Market Share, 2019-2024
        4.3.1 United States Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024)
    4.4 China Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue and Market Share, 2019-2024
        4.4.1 China Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024)
    4.5 Rest of World Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Abecma
        5.2.2 Breyanzi
        5.2.3 Kymriah
        5.2.4 Tecartus
        5.2.5 Yescarta
        5.2.6 Others
    5.3 Market Segment by Type
        5.3.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2019-2024)
        5.3.2 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2025-2030)
        5.3.3 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Diagnostic Center
        6.2.3 Other
    6.3 Market Segment by Application
        6.3.1 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2019-2024)
        6.3.2 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2025-2030)
        6.3.3 World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Autolus Therapeutics
        7.1.1 Autolus Therapeutics Details
        7.1.2 Autolus Therapeutics Major Business
        7.1.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.1.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Autolus Therapeutics Recent Developments/Updates
        7.1.6 Autolus Therapeutics Competitive Strengths & Weaknesses
    7.2 CARsgen Therapeutics
        7.2.1 CARsgen Therapeutics Details
        7.2.2 CARsgen Therapeutics Major Business
        7.2.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.2.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 CARsgen Therapeutics Recent Developments/Updates
        7.2.6 CARsgen Therapeutics Competitive Strengths & Weaknesses
    7.3 Juno Therapeutics
        7.3.1 Juno Therapeutics Details
        7.3.2 Juno Therapeutics Major Business
        7.3.3 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.3.4 Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 Juno Therapeutics Recent Developments/Updates
        7.3.6 Juno Therapeutics Competitive Strengths & Weaknesses
    7.4 Sorrento Therapeutics
        7.4.1 Sorrento Therapeutics Details
        7.4.2 Sorrento Therapeutics Major Business
        7.4.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.4.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Sorrento Therapeutics Recent Developments/Updates
        7.4.6 Sorrento Therapeutics Competitive Strengths & Weaknesses
    7.5 bluebird bio
        7.5.1 bluebird bio Details
        7.5.2 bluebird bio Major Business
        7.5.3 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.5.4 bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 bluebird bio Recent Developments/Updates
        7.5.6 bluebird bio Competitive Strengths & Weaknesses
    7.6 CELGENE CORPORATION
        7.6.1 CELGENE CORPORATION Details
        7.6.2 CELGENE CORPORATION Major Business
        7.6.3 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.6.4 CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 CELGENE CORPORATION Recent Developments/Updates
        7.6.6 CELGENE CORPORATION Competitive Strengths & Weaknesses
    7.7 Eureka Therapeutics
        7.7.1 Eureka Therapeutics Details
        7.7.2 Eureka Therapeutics Major Business
        7.7.3 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.7.4 Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.7.5 Eureka Therapeutics Recent Developments/Updates
        7.7.6 Eureka Therapeutics Competitive Strengths & Weaknesses
    7.8 Avacta Life Sciences
        7.8.1 Avacta Life Sciences Details
        7.8.2 Avacta Life Sciences Major Business
        7.8.3 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.8.4 Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.8.5 Avacta Life Sciences Recent Developments/Updates
        7.8.6 Avacta Life Sciences Competitive Strengths & Weaknesses
    7.9 Calyxt
        7.9.1 Calyxt Details
        7.9.2 Calyxt Major Business
        7.9.3 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.9.4 Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.9.5 Calyxt Recent Developments/Updates
        7.9.6 Calyxt Competitive Strengths & Weaknesses
    7.10 Celyad Oncology SA
        7.10.1 Celyad Oncology SA Details
        7.10.2 Celyad Oncology SA Major Business
        7.10.3 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.10.4 Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.10.5 Celyad Oncology SA Recent Developments/Updates
        7.10.6 Celyad Oncology SA Competitive Strengths & Weaknesses
    7.11 Fortress Biotech
        7.11.1 Fortress Biotech Details
        7.11.2 Fortress Biotech Major Business
        7.11.3 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.11.4 Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.11.5 Fortress Biotech Recent Developments/Updates
        7.11.6 Fortress Biotech Competitive Strengths & Weaknesses
    7.12 IMMUNE THERAPEUTICS
        7.12.1 IMMUNE THERAPEUTICS Details
        7.12.2 IMMUNE THERAPEUTICS Major Business
        7.12.3 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.12.4 IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.12.5 IMMUNE THERAPEUTICS Recent Developments/Updates
        7.12.6 IMMUNE THERAPEUTICS Competitive Strengths & Weaknesses
    7.13 Gilead Sciences
        7.13.1 Gilead Sciences Details
        7.13.2 Gilead Sciences Major Business
        7.13.3 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.13.4 Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.13.5 Gilead Sciences Recent Developments/Updates
        7.13.6 Gilead Sciences Competitive Strengths & Weaknesses
    7.14 Novartis AG
        7.14.1 Novartis AG Details
        7.14.2 Novartis AG Major Business
        7.14.3 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.14.4 Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.14.5 Novartis AG Recent Developments/Updates
        7.14.6 Novartis AG Competitive Strengths & Weaknesses
    7.15 Alaunos Therapeutics
        7.15.1 Alaunos Therapeutics Details
        7.15.2 Alaunos Therapeutics Major Business
        7.15.3 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.15.4 Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.15.5 Alaunos Therapeutics Recent Developments/Updates
        7.15.6 Alaunos Therapeutics Competitive Strengths & Weaknesses
    7.16 Poseida Therapeutics
        7.16.1 Poseida Therapeutics Details
        7.16.2 Poseida Therapeutics Major Business
        7.16.3 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
        7.16.4 Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024)
        7.16.5 Poseida Therapeutics Recent Developments/Updates
        7.16.6 Poseida Therapeutics Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Chain
    8.2 Chimeric Antigen Receptor (CAR)-T Cell Therapy Upstream Analysis
    8.3 Chimeric Antigen Receptor (CAR)-T Cell Therapy Midstream Analysis
    8.4 Chimeric Antigen Receptor (CAR)-T Cell Therapy Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Chimeric Antigen Receptor (CAR)-T Cell Therapy Players in 2023
    Table 12. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Company Evaluation Quadrant
    Table 14. Head Office of Key Chimeric Antigen Receptor (CAR)-T Cell Therapy Player
    Table 15. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Type Footprint
    Table 16. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market: Company Product Application Footprint
    Table 17. Chimeric Antigen Receptor (CAR)-T Cell Therapy Mergers & Acquisitions Activity
    Table 18. United States VS China Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share (2019-2024)
    Table 23. China Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Chimeric Antigen Receptor (CAR)-T Cell Therapy Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share (2019-2024)
    Table 29. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application (2025-2030) & (USD Million)
    Table 35. Autolus Therapeutics Basic Information, Area Served and Competitors
    Table 36. Autolus Therapeutics Major Business
    Table 37. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 38. Autolus Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Autolus Therapeutics Recent Developments/Updates
    Table 40. Autolus Therapeutics Competitive Strengths & Weaknesses
    Table 41. CARsgen Therapeutics Basic Information, Area Served and Competitors
    Table 42. CARsgen Therapeutics Major Business
    Table 43. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 44. CARsgen Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. CARsgen Therapeutics Recent Developments/Updates
    Table 46. CARsgen Therapeutics Competitive Strengths & Weaknesses
    Table 47. Juno Therapeutics Basic Information, Area Served and Competitors
    Table 48. Juno Therapeutics Major Business
    Table 49. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 50. Juno Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. Juno Therapeutics Recent Developments/Updates
    Table 52. Juno Therapeutics Competitive Strengths & Weaknesses
    Table 53. Sorrento Therapeutics Basic Information, Area Served and Competitors
    Table 54. Sorrento Therapeutics Major Business
    Table 55. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 56. Sorrento Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Sorrento Therapeutics Recent Developments/Updates
    Table 58. Sorrento Therapeutics Competitive Strengths & Weaknesses
    Table 59. bluebird bio Basic Information, Area Served and Competitors
    Table 60. bluebird bio Major Business
    Table 61. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 62. bluebird bio Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. bluebird bio Recent Developments/Updates
    Table 64. bluebird bio Competitive Strengths & Weaknesses
    Table 65. CELGENE CORPORATION Basic Information, Area Served and Competitors
    Table 66. CELGENE CORPORATION Major Business
    Table 67. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 68. CELGENE CORPORATION Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 69. CELGENE CORPORATION Recent Developments/Updates
    Table 70. CELGENE CORPORATION Competitive Strengths & Weaknesses
    Table 71. Eureka Therapeutics Basic Information, Area Served and Competitors
    Table 72. Eureka Therapeutics Major Business
    Table 73. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 74. Eureka Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 75. Eureka Therapeutics Recent Developments/Updates
    Table 76. Eureka Therapeutics Competitive Strengths & Weaknesses
    Table 77. Avacta Life Sciences Basic Information, Area Served and Competitors
    Table 78. Avacta Life Sciences Major Business
    Table 79. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 80. Avacta Life Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 81. Avacta Life Sciences Recent Developments/Updates
    Table 82. Avacta Life Sciences Competitive Strengths & Weaknesses
    Table 83. Calyxt Basic Information, Area Served and Competitors
    Table 84. Calyxt Major Business
    Table 85. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 86. Calyxt Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 87. Calyxt Recent Developments/Updates
    Table 88. Calyxt Competitive Strengths & Weaknesses
    Table 89. Celyad Oncology SA Basic Information, Area Served and Competitors
    Table 90. Celyad Oncology SA Major Business
    Table 91. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 92. Celyad Oncology SA Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 93. Celyad Oncology SA Recent Developments/Updates
    Table 94. Celyad Oncology SA Competitive Strengths & Weaknesses
    Table 95. Fortress Biotech Basic Information, Area Served and Competitors
    Table 96. Fortress Biotech Major Business
    Table 97. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 98. Fortress Biotech Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 99. Fortress Biotech Recent Developments/Updates
    Table 100. Fortress Biotech Competitive Strengths & Weaknesses
    Table 101. IMMUNE THERAPEUTICS Basic Information, Area Served and Competitors
    Table 102. IMMUNE THERAPEUTICS Major Business
    Table 103. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 104. IMMUNE THERAPEUTICS Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 105. IMMUNE THERAPEUTICS Recent Developments/Updates
    Table 106. IMMUNE THERAPEUTICS Competitive Strengths & Weaknesses
    Table 107. Gilead Sciences Basic Information, Area Served and Competitors
    Table 108. Gilead Sciences Major Business
    Table 109. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 110. Gilead Sciences Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 111. Gilead Sciences Recent Developments/Updates
    Table 112. Gilead Sciences Competitive Strengths & Weaknesses
    Table 113. Novartis AG Basic Information, Area Served and Competitors
    Table 114. Novartis AG Major Business
    Table 115. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 116. Novartis AG Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 117. Novartis AG Recent Developments/Updates
    Table 118. Novartis AG Competitive Strengths & Weaknesses
    Table 119. Alaunos Therapeutics Basic Information, Area Served and Competitors
    Table 120. Alaunos Therapeutics Major Business
    Table 121. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 122. Alaunos Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 123. Alaunos Therapeutics Recent Developments/Updates
    Table 124. Poseida Therapeutics Basic Information, Area Served and Competitors
    Table 125. Poseida Therapeutics Major Business
    Table 126. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Product and Services
    Table 127. Poseida Therapeutics Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 128. Global Key Players of Chimeric Antigen Receptor (CAR)-T Cell Therapy Upstream (Raw Materials)
    Table 129. Chimeric Antigen Receptor (CAR)-T Cell Therapy Typical Customers
List of Figure
    Figure 1. Chimeric Antigen Receptor (CAR)-T Cell Therapy Picture
    Figure 2. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue (2019-2030) & (USD Million)
    Figure 13. Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Chimeric Antigen Receptor (CAR)-T Cell Therapy by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Chimeric Antigen Receptor (CAR)-T Cell Therapy Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Chimeric Antigen Receptor (CAR)-T Cell Therapy Markets in 2023
    Figure 27. United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Chimeric Antigen Receptor (CAR)-T Cell Therapy Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type in 2023
    Figure 31. Abecma
    Figure 32. Breyanzi
    Figure 33. Kymriah
    Figure 34. Tecartus
    Figure 35. Yescarta
    Figure 36. Others
    Figure 37. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Type (2019-2030)
    Figure 38. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 39. World Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size Market Share by Application in 2023
    Figure 40. Hospital
    Figure 41. Diagnostic Center
    Figure 42. Other
    Figure 43. Chimeric Antigen Receptor (CAR)-T Cell Therapy Industrial Chain
    Figure 44. Methodology
    Figure 45. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Autolus Therapeutics
CARsgen Therapeutics
Juno Therapeutics
Sorrento Therapeutics
bluebird bio
CELGENE CORPORATION
Eureka Therapeutics
Avacta Life Sciences
Calyxt
Celyad Oncology SA
Fortress Biotech
IMMUNE THERAPEUTICS
Gilead Sciences
Novartis AG
Alaunos Therapeutics
Poseida Therapeutics

Related Reports

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 25 Mar 2023

date Medical Care

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2023-2029

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Supply, Demand and Key Producers, 2023-2029

date 25 Mar 2023

date Medical Care

The global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 14 Jan 2024

date Medical Care

According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR)-T Cell Therapy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Chimeric Antigen Receptor (CAR) T-Cell Therapy

Chimeric Antigen Receptor (CAR)-T Cell Therapy

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>